The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

Scientists and analysts express concern that the newly appointed members—which include known anti-vaxxers—could relitigate ...

The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by rising vaccine uptake, impr ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...